Review Article
Digital Therapeutics for Migraine: Core Categories, Clinical Evidence, and Future Perspectives
Mengna Yang
,
Jinyan Shao,
Mario Fernando Prieto Peres*,
Kaiming Liu*
Issue:
Volume 2, Issue 2, June 2026
Pages:
31-37
Received:
7 April 2026
Accepted:
16 April 2026
Published:
28 April 2026
DOI:
10.11648/j.ijpr.20260202.11
Downloads:
Views:
Abstract: Research Background: Migraine is one of the most common neurological disorders worldwide, with a prevalence of approximately 14–15%, and ranks second in terms of disability burden. Traditional pharmacological treatments face limitations in efficacy, adverse effects, and high costs, driving an increasing demand for non-pharmacological interventions. As evidence-based, software-driven therapeutic approaches, digital therapeutics offer a new direction for migraine management. Research Objectives and Methods: This study aims to systematically review the core categories, clinical evidence, and future development directions of digital therapies for migraine. A scoping review methodology was employed, with a literature search conducted in PubMed, Embase, and IEEE Xplore databases from 2018 to March 2026. Qualitative analysis of 48 articles was performed in accordance with the PRISMA-ScR guidelines. The study identified four major categories of digital therapeutics: digital cognitive behavioral therapy, digital neurostimulation technology, smart monitoring and early warning systems, and virtual reality combined with biofeedback therapy. Clinical evidence indicates that these interventions can effectively reduce headache frequency and improve comorbid symptoms such as anxiety and insomnia; however, limitations include methodological heterogeneity and varying evidence quality. Conclusion: It was concluded that digital therapies are an important component of comprehensive migraine management. Future efforts should focus on conducting large-scale, long-term randomized controlled trials to accumulate high-quality evidence, while simultaneously refining regulatory frameworks and developing personalized closed-loop adaptive systems, with the aim of providing better treatment options for hundreds of millions of patients worldwide.
Abstract: Research Background: Migraine is one of the most common neurological disorders worldwide, with a prevalence of approximately 14–15%, and ranks second in terms of disability burden. Traditional pharmacological treatments face limitations in efficacy, adverse effects, and high costs, driving an increasing demand for non-pharmacological interventions....
Show More
